Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

drugsJuly 04, 2019

Tag: FDA , Xpovio , Selinexor , myeloma

PharmaSources Customer Service